Vigil Neuroscience to Present at Cantor Global Healthcare Conference
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in the Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 9:45 a.m. ET.
Interested parties can register for the live webcast through a provided link. The webcast will also be accessible on Vigil Neuroscience's website in the 'Investors' section under 'Events & Presentations'. An archived version of the webcast will remain available for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL), un'azienda biotecnologica in fase clinica che si concentra su trattamenti basati sulle microglia per le malattie neurodegenerative, ha annunciato la sua partecipazione alla Cantor Global Healthcare Conference. La direzione dell'azienda condurrà un fireside chat giovedì 19 settembre 2024, alle 9:45 ET.
Le parti interessate possono registrarsi per il webcast dal vivo tramite un link fornito. Il webcast sarà inoltre accessibile sul sito web di Vigil Neuroscience nella sezione 'Investitori' sotto 'Eventi e Presentazioni'. Una versione archiviata del webcast rimarrà disponibile per circa 90 giorni dopo l'evento.
Vigil Neuroscience (Nasdaq: VIGL), una compañía biotecnológica en etapa clínica enfocada en tratamientos basados en microglía para enfermedades neurodegenerativas, ha anunciado su participación en la Cantor Global Healthcare Conference. La dirección de la compañía participará en un fireside chat el jueves 19 de septiembre de 2024, a las 9:45 a.m. ET.
Las partes interesadas pueden registrarse para el webcast en vivo a través de un enlace proporcionado. El webcast también estará accesible en el sitio web de Vigil Neuroscience en la sección 'Inversores' bajo 'Eventos y Presentaciones'. Una versión archivada del webcast permanecerá disponible durante aproximadamente 90 días después del evento.
비질 신경과학 (Nasdaq: VIGL)은 신경퇴행성 질환을 위한 미세아 교세포 기반 치료법에 중점을 둔 임상 단계의 바이오텍 회사로, 칸토 글로벌 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다. 회사 경영진은 2024년 9월 19일 목요일 오전 9시 45분 ET에 파이어사이드 차트를 진행할 예정입니다.
관심 있는 분들은 제공된 링크를 통해 라이브 웨비나에 등록할 수 있습니다. 웨비나는 비질 신경과학 웹사이트의 '투자자' 섹션의 '이벤트 및 발표' 아래에서 접근할 수 있습니다. 웨비나의 아카이브 버전은 이벤트 후 약 90일 동안 이용 가능합니다.
Vigil Neuroscience (Nasdaq: VIGL), une société biopharmaceutique en phase clinique se concentrant sur des traitements basés sur les microglies pour les maladies neurodégénératives, a annoncé sa participation à la Cantor Global Healthcare Conference. La direction de l'entreprise participera à un fireside chat le jeudi 19 septembre 2024 à 9h45 ET.
Les parties intéressées peuvent s'inscrire pour le webinaire en direct via un lien fourni. Le webinaire sera également accessible sur le site de Vigil Neuroscience dans la section 'Investisseurs' sous 'Événements et Présentations'. Une version archivée du webinaire restera disponible pendant environ 90 jours après l'événement.
Vigil Neuroscience (Nasdaq: VIGL), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf mikroglia-basierte Behandlungen für neurodegenerative Erkrankungen konzentriert, hat seine Teilnahme an der Cantor Global Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird am Donnerstag, den 19. September 2024, um 9:45 Uhr ET an einem Fireside Chat teilnehmen.
Interessierte Parteien können sich über einen bereitgestellten Link für das Live-Webcast registrieren. Das Webcast wird auch auf der Website von Vigil Neuroscience im Bereich 'Investoren' unter 'Veranstaltungen & Präsentationen' zugänglich sein. Eine archivierte Version des Webcasts wird voraussichtlich etwa 90 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.
To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When is Vigil Neuroscience (VIGL) presenting at the Cantor Global Healthcare Conference?
How can I watch Vigil Neuroscience's (VIGL) presentation at the Cantor Global Healthcare Conference?
How long will the archived webcast of Vigil Neuroscience's (VIGL) presentation be available?
What is the focus of Vigil Neuroscience's (VIGL) research?
